×
About 465 results

ALLMedicine™ Lambert-eaton Myasthenic Syndrome Center

Research & Reviews  211 results

Lambert-Eaton Myasthenic Syndrome and Dermatomyositis With Anti-TIF1-gamma Autoantibody...
https://doi.org/10.1097/CND.0000000000000318
Journal of Clinical Neuromuscular Disease; Isfort M, Mnatsakanova D et. al.

Feb 17th, 2021 - Lambert-Eaton myasthenic syndrome (LEMS) is a presynaptic neuromuscular junction disorder, and dermatomyositis (DM) is an idiopathic inflammatory myopathy. LEMS and DM are uncommon conditions that can present similarly and are often associated wit...

Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
https://doi.org/10.1016/j.ncl.2020.09.007
Neurologic Clinics; Bodkin C, Pascuzzi RM

Nov 23rd, 2020 - Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders of neuromuscular transmission in clinical practice. Disorders of the neuromuscular junction (NMJ) are characterized by fluctuating and fatigable weak...

Assessment of the compound muscle action potential amplitude return time between exerci...
https://doi.org/10.1002/mus.27060
Muscle & Nerve; Oh SJ

Sep 7th, 2020 - When performing postexercise facilitation (PEF) as part of the repetitive nerve stimulation (RNS) test in Lambert-Eaton myasthenic syndrome (LEMS), it is important to avoid any influence of the previous exercise or RNS test on the compound muscle ...

Lowering the cutoff value for increment increases the sensitivity for the diagnosis of ...
https://doi.org/10.1002/mus.26885
Muscle & Nerve REFERENCES; Lipka AF, Titulaer MJ et. al.

Apr 15th, 2020 - Increment of compound muscle action potential amplitude is a diagnostic hallmark of Lambert-Eaton myasthenic syndrome (LEMS). Making a diagnosis can be challenging, therefore, a proper cutoff for abnormal increment is highly relevant for improved ...

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 4th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

see more →

Guidelines  3 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 4th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

Guidelines for treatment of autoimmune neuromuscular transmission disorders.
https://doi.org/10.1111/j.1468-1331.2010.03019.x
European Journal of Neurology; Skeie GO, Apostolski S et. al.

Apr 20th, 2010 - Important progress has been made in our understanding of the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) and neuromyotonia (Isaacs' syndrome). To prepare consensus guideli...

FIRDAPSE® (amifampridine) | Healthcare Professional Site
https://www.firdapsehcp.com/

FIRDAPSE® (amifampridine)—the only FDA-approved, evidence-based treatment for adult patients with Lambert-Eaton myasthenic syndrome (LEMS). Please visit the website for Important Safety Information and Prescribing Information.

see more →

Drugs  3 results see all →

Clinicaltrials.gov  231 results

Lambert-Eaton Myasthenic Syndrome and Dermatomyositis With Anti-TIF1-gamma Autoantibody...
https://doi.org/10.1097/CND.0000000000000318
Journal of Clinical Neuromuscular Disease; Isfort M, Mnatsakanova D et. al.

Feb 17th, 2021 - Lambert-Eaton myasthenic syndrome (LEMS) is a presynaptic neuromuscular junction disorder, and dermatomyositis (DM) is an idiopathic inflammatory myopathy. LEMS and DM are uncommon conditions that can present similarly and are often associated wit...

Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
https://doi.org/10.1016/j.ncl.2020.09.007
Neurologic Clinics; Bodkin C, Pascuzzi RM

Nov 23rd, 2020 - Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders of neuromuscular transmission in clinical practice. Disorders of the neuromuscular junction (NMJ) are characterized by fluctuating and fatigable weak...

Firdapse - amifampridine phosphate tablet-Catalyst Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f

Oct 29th, 2020 - FIRDAPSE® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. (1)

Ruzurgi - amifampridine tablet-Jacobus Pharmaceutical Company,Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9

Oct 6th, 2020 - RUZURGI is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. RUZURGI is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patien...

Assessment of the compound muscle action potential amplitude return time between exerci...
https://doi.org/10.1002/mus.27060
Muscle & Nerve; Oh SJ

Sep 7th, 2020 - When performing postexercise facilitation (PEF) as part of the repetitive nerve stimulation (RNS) test in Lambert-Eaton myasthenic syndrome (LEMS), it is important to avoid any influence of the previous exercise or RNS test on the compound muscle ...

see more →

News  17 results

Ruzurgi approved for Lambert-Eaton myasthenic syndrome in patients under age 17
https://www.mdedge.com/clinicalneurologynews/article/200494/neuromuscular-disorders/ruzurgi-approved-lambert-eaton?channel=285
Mary Jo M. Dales, Clinical Neurology News

May 8th, 2019 - Amifampridine (Ruzurgi) has been approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder, in patients aged 6 to less than 17 years, according to a statement from the Food and Drug Administra.

FDA OKs First Treatment for Kids With Lambert-Eaton Myasthenic Syndrome
https://www.staging.medscape.com/viewarticle/912722

May 7th, 2019 - The US Food and Drug Administration (FDA) has approved the first treatment for children with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Amifampridine (Ruzurgi, Jacobus Pharmacuetical) is an oral potassium channel blocker...

FDA OKs First Treatment for Kids With Lambert-Eaton Myasthenic Syndrome
https://www.medscape.com/viewarticle/912722

May 7th, 2019 - The US Food and Drug Administration (FDA) has approved the first treatment for children with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Amifampridine (Ruzurgi, Jacobus Pharmacuetical) is an oral potassium channel blocker...

Catalyst Pharma sees net price of drug, once free, topping $300,000
https://www.reuters.com/article/us-catalyst-pharms-drugpricing/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000-idUSKCN1Q0286

Feb 11th, 2019 - NEW YORK (Reuters) - Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discoun...

Senator Sanders asks why drug, once free, now costs $375k
https://www.reuters.com/article/us-usa-healthcare-catalyst/senator-sanders-asks-why-drug-once-free-now-costs-375k-idUSKCN1PT0ZJ

Feb 4th, 2019 - WASHINGTON (Reuters) - U.S. Senator Bernie Sanders sent a letter to Catalyst Pharmaceuticals (CPRX.O) on Monday asking it to justify its decision to charge $375,000 annually for a medication that for years has been available to patients for free. ...

see more →